TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

·1 min read
TG Therapeutics, Inc.
TG Therapeutics, Inc.

Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ET

NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference taking place next week. A webcast of the presentation will be available for on demand download beginning on Tuesday, May 24, 2022, at 7:00 AM ET through Thursday May 26, 2022, on the conference website.

The webcast will also be available on TG’s website at

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). For more information, visit, and follow us on Twitter @TGTherapeutics and Linkedin.

UKONIQ® is a registered trademark of TG Therapeutics, Inc.


Investor Relations
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Telephone: 1.877.575.TGTX (8489), Option 6

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting